ANI Pharmaceuticals (ANIP) Scheduled to Post Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to post its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect ANI Pharmaceuticals to post earnings of $1.09 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same period last year, the firm posted $1.06 EPS. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $58.40 on Thursday. The company has a market capitalization of $1.23 billion, a P/E ratio of 49.91 and a beta of 0.71. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $58.78 and a two-hundred day moving average price of $61.60.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ANIP shares. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.